PT  - JOURNAL ARTICLE
AU  - Tun Wiltgen
AU  - Julian McGinnis
AU  - Sarah Schlaeger
AU  - CuiCi Voon
AU  - Achim Berthele¹
AU  - Daria Bischl
AU  - Lioba Grundl
AU  - Nikolaus Will
AU  - Marie Metz
AU  - David Schinz
AU  - Dominik Sepp
AU  - Philipp Prucker
AU  - Benita Schmitz-Koep
AU  - Claus Zimmer
AU  - Bjoern Menze
AU  - Daniel Rueckert
AU  - Bernhard Hemmer
AU  - Jan Kirschke
AU  - Mark Mühlau
AU  - Benedikt Wiestler
TI  - LST-AI: a Deep Learning Ensemble for Accurate MS Lesion Segmentation
AID  - 10.1101/2023.11.23.23298966
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.11.23.23298966
4099  - http://medrxiv.org/content/early/2023/11/24/2023.11.23.23298966.short
4100  - http://medrxiv.org/content/early/2023/11/24/2023.11.23.23298966.full
AB  - Automated segmentation of brain white matter lesions is crucial for both clinical assessment and scientific research in multiple sclerosis (MS). Over a decade ago, we introduced a lesion segmentation tool, LST, engineered with a lesion growth algorithm (LST-LGA). While recent lesion segmentation approaches have leveraged artificial intelligence (AI), they often remain proprietary and difficult to adopt. Here, we present LST-AI, an advanced deep learning-based extension of LST that consists of an ensemble of three 3D-UNets.LST-AI specifically addresses the imbalance between white matter (WM) lesions and non-lesioned WM. It employs a composite loss function incorporating binary cross-entropy and Tversky loss to improve segmentation of the highly heterogeneous MS lesions. We train the network ensemble on 491 MS pairs of T1w and FLAIR images, collected in-house from a 3T MRI scanner, and expert neuroradiologists manually segmented the utilized lesion maps for training. LST-AI additionally includes a lesion location annotation tool, labeling lesion location according to the 2017 McDonald criteria (periventricular, infratentorial, juxtacortical, subcortical). We conduct evaluations on 270 test cases —comprising both in-house (n=167) and publicly available data (n=103)—using the Anima segmentation validation tools and compare LST-AI with several publicly available lesion segmentation models.Our empirical analysis shows that LST-AI achieves superior performance compared to existing methods. Its Dice and F1 scores exceeded 0.5, outperforming LST-LGA, LST-LPA, SAMSEG, and the popular nnUNet framework, which all scored below 0.45. Notably, LST-AI demonstrated exceptional performance on the MSSEG-1 challenge dataset, an international WM lesion segmentation challenge, with a Dice score of 0.65 and an F1 score of 0.63—surpassing all other competing models at the time of the challenge. With increasing lesion volume, the lesion detection rate rapidly increased with a detection rate of >75% for lesions larger than 60mm3.Given its higher segmentation performance, we recommend that research groups currently using LST-LGA transition to LST-AI. To facilitate broad adoption, we are releasing LST-AI as an open-source model, available as a command-line tool, dockerized container, or Python script, enabling diverse applications across multiple platforms.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board (Ethikkommission) of the School of Medicine and Health, TU Munich, approved the retrospective use of anonymized local MR studies of Multiple Sclerosis patients for this study (IRB# 2022-261-S-DFG-SR). Given the retrospective nature of our study (and anonymization of data), Informed Consent was waived.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors